| BIOBV Stock | | | EUR 2.29 0.03 1.33% |
Managing Director
Graham Johnson is Managing Director of Biohit Healthcare Ltd. of Biohit Oyj B since 2011.
| Tenure | 13 years |
| Phone | 358 9773 861 |
| Web | https://www.biohithealthcare.com |
Biohit Oyj Management Efficiency
The company has return on total asset
(ROA) of
0.0652 % which means that it generated a profit of $0.0652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.0645 %, meaning that it generated $0.0645 on every $100 dollars invested by stockholders. Biohit Oyj's management efficiency ratios could be used to measure how well Biohit Oyj manages its routine affairs as well as how well it operates its assets and liabilities.
Biohit Oyj B has accumulated 59
K in total debt with debt to equity ratio
(D/E) of 0.3, which may suggest the company is not taking enough advantage from borrowing. Biohit Oyj B has a current ratio of 7.63, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biohit Oyj until it has trouble settling it off, either with new capital or with free cash flow. So, Biohit Oyj's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biohit Oyj B sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biohit to invest in growth at high rates of return. When we think about Biohit Oyj's use of debt, we should always consider it together with cash and equity.
Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company was founded in 1988 and is headquartered in Helsinki, Finland. Biohit Oyj operates under Healthcare Services classification in Finland and is traded on Helsinki Exchange. It employs 49 people. Biohit Oyj B (BIOBV) is traded on Helsinki Exchange in Finland and employs 44 people.
Management Performance
Biohit Oyj B Leadership Team
Elected by the shareholders, the Biohit Oyj's board of directors comprises two types of representatives: Biohit Oyj inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biohit. The board's role is to monitor Biohit Oyj's management team and ensure that shareholders' interests are well served. Biohit Oyj's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biohit Oyj's outside directors are responsible for providing unbiased perspectives on the board's policies.
Biohit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biohit Oyj a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Biohit Stock
Biohit Oyj financial ratios help investors to determine whether Biohit Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biohit with respect to the benefits of owning Biohit Oyj security.